Log in to search using one of your social media accounts:

 

Severe Psoriasis Linked to Higher Risk of Earlier Death

Title: Severe Psoriasis Linked to Higher Risk of Earlier DeathCategory: Health NewsCreated: 9/5/2017 12:00:00 AMLast Editorial Review: 9/6/2017 12:00:00 AM
Source: MedicineNet Skin General - Category: Dermatology Source Type: news

Related Links:

This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
A study shows that not only is psoriasis independently tied to risk of type 2 diabetes, but that the risk rises with severity of the skin disease.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Diabetes Source Type: news
Summary BackgroundInfections are associated with biological therapies in psoriasis. ObjectivesTo summarize the incidence of infections in patients with moderate‐to‐severe psoriasis treated with ixekizumab, an anti‐interleukin‐17A monoclonal antibody. MethodsInfections are summarized from an integrated database of seven controlled and uncontrolled ixekizumab psoriasis trials. Data are presented from placebo‐controlled induction (weeks 0–12; UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3) and maintenance periods (weeks 12–60; UNCOVER‐1 and UNCOVER‐2), and all patients exposed to ixekizumab pooled from all...
Source: British Journal of Dermatology - Category: Dermatology Authors: Tags: Clinical Trial Source Type: research
ConclusionsNew‐onset anti‐TNF‐α‐induced eruptions previously classified as psoriasis or spongiotic dermatitis (eczema) exhibit a molecular profile that is different from either of these disorders.This article is protected by copyright. All rights reserved.
Source: British Journal of Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
The FDA has given a regulatory green light to the first device that reduces opioid withdrawal symptoms. The NSS-2 Bridge from Innovative Health Solutions, a Versailles, Indiana firm, is stuck to the skin behind the ear and relies on four electrodes that are attached around the ear. The electrodes are used to deliver electric current to a set of occipital and cranial nerves (V, VII, IX, and X), hopefully helping addicts to avoid agitation, insomnia, and other symptoms of kicking opioids. The same device was approved by the FDA three years ago for use in acupuncture and the current approval went under the de novo review...
Source: Medgadget - Category: Medical Devices Authors: Tags: Medicine Neurology Pain Management Psychiatry Source Type: blogs
Accurate Diagnosis and Evidence-Based Comprehensive Care in Psoriasis: The Integral Role of Family Practice and General Practice Physicians
Source: PeerView CME/CE Audio Podcast - Immunology - Category: Allergy & Immunology Authors: Tags: Science, Medicine Source Type: podcasts
In this report, we demonstrated that in vitro, DZ2002 significantly decreased the expression of pro-inflammatory cytokines and adhesion molecule including IL-1α, IL-1β, IL-6, IL-8, TNF-α and ICAM-1 by inhibiting the phosphorylation of p38 MAPK, ERK and JNK in TNF-α/IFN-γ-stimulated HaCaT human keratinocytes. Topical administration of DZ2002 alleviated the imiquimod (IMQ)-induced psoriasis-like skin lesions and inflammation in mice, the therapeutic effect was comparable with the Calcipotriol. Moreover, the inflammatory skin disorder was restored by DZ2002 treatment characterized by reducing both...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
ConclusionDespite the absence of a significant difference between apremilast and placebo in proportion of patients achieving a PPPGA of 0/1, the presence of significant differences observed for several secondary endpoints suggests that apremilast may have a role in the treatment of moderate‐to‐severe palmoplantar psoriasis.
Source: Journal of the European Academy of Dermatology and Venereology - Category: Dermatology Authors: Tags: Original Article Source Type: research
ConclusionBiologic therapy is effective and well-tolerated for the treatment of hyperkeratotic PP, but less data are available on the treatment of pustular PP or PPP. Adalimumab, guselkumab, ixekizumab, secukinumab, and ustekinumab all showed  >  80% efficacy for the treatment of hyperkeratotic PP, while infliximab and ustekinumab showed moderate efficacy for the treatment of pustular PP, and infliximab was the most efficacious treatment for PPP.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
Conclusion: The results suggested a pathogenesis mechanism of psoriasis and indicated novel therapeutic targets for psoriasis.Dermatology
Source: Dermatology - Category: Dermatology Source Type: research
More News: Dermatology | Psoriasis | Skin